Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Blood (2016) 128 (22): 4382.

https://doi.org/10.1182/blood.V128.22.4382.4382

Published: 2016

Journal Articles

APT1-Mediated Cross-Talk Between Palmitoylation and Phosphorylation Events of the BCR Pathway Sensitizes CLL Cells Towards BCR-Associated Kinase Inhibitors

Valeska Berg, PhD, Dunja Baatout, M.Sc., Clemens Wendtner, MD, Michael Hallek, Lukas P. Frenzel, MD

Blood (2016) 128 (22): 4361.

https://doi.org/10.1182/blood.V128.22.4361.4361

Published: 2016

Journal Articles

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Blood (2015) 126 (23): 2773.

https://doi.org/10.1182/blood.V126.23.2773.2773

Published: 2015

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

A Complex Molecular Network Controls Palmitoylation-Dependant CD95 Sensitivity Of CLL Cells

Valeska Berg, Nachiket Vartak, PhD, Rainer Claus, MD, Julia Claasen, Marion Rusch, PhD, Christian P. Pallasch, MD, Herbert Waldmann, PhD, Christopher Plass, PhD, Philippe Bastiaens, PhD, Michael Hallek, MD, Christian Hedberg, PhD, Clemens Wendtner, MD, Lukas P. Frenzel, MD

Blood (2013) 122 (21): 4148.

https://doi.org/10.1182/blood.V122.21.4148.4148

Published: 2013

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D., Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 4127.

https://doi.org/10.1182/blood.V122.21.4127.4127

Published: 2013

Journal Articles

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

Udo Holtick, MD PhD, Lukas P. Frenzel, MD, Shimabukuro-Vornhagen Alexander, MD, Sebastian Theurich, MD, Julia Claasen, Christof Scheid, MD, PhD, Michael von-Bergwelt-Baildon, MD PhD, Michael Hallek, MD PhD, Clemens Wendtner, MD, Jens M. Chemnitz, MD

Blood (2013) 122 (21): 4588.

https://doi.org/10.1182/blood.V122.21.4588.4588

Published: 2013

Journal Articles

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Blood (2013) 122 (21): 526.

https://doi.org/10.1182/blood.V122.21.526.526

Published: 2013

Journal Articles

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Christian P. Pallasch, MD, Leskov Ilya, MD, PhD, Yadira M Soto, Christian J. Braun, MD, Nadine Kutsch, MD, Adam Drake, PhD, Lukas P. Frenzel, MD, Bettina Iliopoulou, PhD, Nico van Rooijen, PhD, Clemens Wendtner, MD, Michael Hallek, MD, Jianzhu Chen, PhD, Michael T Hemann, PhD

Blood (2012) 120 (21): 1335.

https://doi.org/10.1182/blood.V120.21.1335.1335

Published: 2012

Journal Articles

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Michael Hallek, MD, Graeme Fraser, Anne-Sophie Michallet, MD, PhD, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, MD, Matt Kalaycio, MD, Stephan Stilgenbauer, MD, Andreas Buehler, Thomas J. Kipps, MD, PhD, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan, MD

Blood (2012) 120 (21): 3925.

https://doi.org/10.1182/blood.V120.21.3925.3925

Published: 2012

Journal Articles

TOSO Deficiency Exerts Impact On BAFF-R Expression, Thereby Causing Impaired B Cell Development in Vivo

Alexandra Schulz, PhD, Yoon Jung Park, Ph.D., Rainer Claus, MD, Hamid Kashkar, PhD, Jens Seeger, PhD, Julia Claasen, Christian P. Pallasch, MD, Christoph Plass, PhD, Michael Hallek, MD, Clemens Wendtner, Lukas P. Frenzel, MD

Blood (2012) 120 (21): 3898.

https://doi.org/10.1182/blood.V120.21.3898.3898

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

B Cell Receptor Stimulation of CLL Cells Leads to Upregulation of IRF4 Proteinexpression Influenced by SNP Expression,

Michaela Patz, PhD, Nina-Felizitas Linde, Lukas P. Frenzel, MD, Christian P. Pallasch, MD, Reinhild Brinker, Julia Claasen, Michael Hallek, MD, Clemens Wendtner, MD

Blood (2011) 118 (21): 3886.

https://doi.org/10.1182/blood.V118.21.3886.3886

Published: 2011

Journal Articles

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Graeme Fraser, Stuart L. Goldberg, MD, Adrian JC Bloor, PhD, FRCP, FRCPath, Stephan Stilgenbauer, Florence Cymbalista, Thomas Kipps, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan

Blood (2011) 118 (21): 2859.

https://doi.org/10.1182/blood.V118.21.2859.2859

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Sebastian Boettcher, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Andreas Buehler, MD, Dirk Winkler, MD, Michael K. Wenger, MD, Myriam Mendila, MD, Clemens Wendtner, MD, Barbara Eichhorst, MD, Hartmut Döhner, MD, Michael Hallek, MD, Michael Kneba, MD

Blood (2011) 118 (21): 1777.

https://doi.org/10.1182/blood.V118.21.1777.1777

Published: 2011

Journal Articles

TOSO-Deficient B Cells Show An Impaired NF-κB and Migration Signaling In Vivo

Alexandra Schulz, Christian P. Pallasch, MD, Michael Hallek, MD, Lukas P. Frenzel, MD, Clemens Wendtner, MD

Blood (2011) 118 (21): 1779.

https://doi.org/10.1182/blood.V118.21.1779.1779

Published: 2011

Journal Articles

Primed for Death: Hypoxia Sensitizes Primary CLL Cells towards Compounds Targeting Mitochondrial Integrity

Lukas P. Frenzel, MD, Malte Huelsemann, Julia Claasen, Reinhild Brinker, Sebastian Theurich, MD, Hans Jiro Becker, Michael S. von Bergwelt-Baildon, MD, PhD, Christian P. Pallasch, MD, Michael Hallek, MD, Clemens Wendtner, MD

Blood (2011) 118 (21): 1767.

https://doi.org/10.1182/blood.V118.21.1767.1767

Published: 2011

Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Blood (2010) 116 (21): 1376.

https://doi.org/10.1182/blood.V116.21.1376.1376

Published: 2010

Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 3609.

https://doi.org/10.1182/blood.V116.21.3609.3609

Published: 2010

NARROW

APT1-Mediated Cross-Talk Between Palmitoylation and Phosphorylation Events of the BCR Pathway Sensitizes CLL Cells Towards BCR-Associated Kinase Inhibitors

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

A Complex Molecular Network Controls Palmitoylation-Dependant CD95 Sensitivity Of CLL Cells

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

TOSO Deficiency Exerts Impact On BAFF-R Expression, Thereby Causing Impaired B Cell Development in Vivo

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

B Cell Receptor Stimulation of CLL Cells Leads to Upregulation of IRF4 Proteinexpression Influenced by SNP Expression,

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

TOSO-Deficient B Cells Show An Impaired NF-κB and Migration Signaling In Vivo

Primed for Death: Hypoxia Sensitizes Primary CLL Cells towards Compounds Targeting Mitochondrial Integrity

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only